LATEST NEWS

Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.